YAZ and FDA: Attorney Wendy Fleishman Comments on Latest Yaz Birth Control Safety News
The U.S. Food and Drug Administration issued a statement today that the FDA remains concerned, but has not yet reached a conclusion, about the potential increased risk of blood clots from Drospirenone-containing birth control pills such as YAZ, YASMIN, BEYAZ, and OCELLA, among others. Preliminary results from an FDA-sponsored study of 800,000 women taking birth control pills shows that there is a 1.5 increased risk among Drospirenone-containing pill users.
To address these concerns, the FDA has scheduled an important meeting for December 8, 2011. The FDA will hear testimony concerning these studies and the safety of these medications. The meeting is open to the public.
Commenting on the FDA warning, Wendy Fleishman, a prominent personal injury attorney with the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, stated, “Too many active and healthy women have suddenly died from, or suffered severe, life-threatening blood clots allegedly caused by taking Drospirenone-containing birth control pills, like YAZ. We are wholly supportive of birth control choices for young women, but women need to be accurately informed of the potential risks when they take a birth control pill. We hope that the FDA’s review will cause Bayer to take the responsible course of action and fully disclose the dangers this drug poses.”
Ms. Fleishman is representing women nationwide in Yaz lawsuits.
